The Q4 guide implies slower growth. Management expects revenue to rise 4% to 6% and gross margin to fall back to 26% to 28%, which suggests that the third-quarter margin may include temporary benefits or a heavierDepreciationcharge to come. Co-chief executive Zhao Haijun said …
Oil did not react to the talks. Brent rose 3.30% to USD 95.82 and West Texas Intermediate rose 2.55% to USD 88.74, because of attacks in the Middle East. Houthi forces claimed strikes on a pumping station of Saudi Arabia's East-West pipeline, aFacilityat Yanbu …
Key HighlightsThe Brazilian real weakened sharply on November 12, 2026, with USD/BRL rising 1.58% to 5.6507, the real's weakest level since June 2025.The move was linked to discontent with Brazil's fiscal package, and the Ibovespaindexfell 0.43% to 171,324 on soured local sentiment.The dollar index …
The company said the timing reflects assay refinement timelines and ongoing dialogue with the FDA, and that the plan depends on the outcome of that dialogue. Market data show the submission had previously been targeted for the fourth quarter of 2026.
Revenue fell to $4.2 million from $9.6 million a year earlier, below market estimates of about $7.8 million. The net loss widened to $87.7 million, or $0.68 per share, from $60.0 million, and market estimates had pointed to a loss per share of roughly …
Management said third quarter revenue was below its expectations. It pointed to several of its largest accounts, citing isolated account-level issues and field organization changes that caused more disruption than anticipated, and said scheduled fourth quarter cases have begun to recover.
The company said the pre-specified 80th event has occurred in REGAL and that the final analysis is underway. It expects to report topline primary endpoint results this month, narrowing the fourth-quarter timeframe given earlier. No efficacy data from the trial has been disclosed.
The offering covers 15,000,000 shares at $10.00 each, about 17.5% below the prior close, for expected gross proceeds of $150 million beforeUnderwritingdiscounts and expenses. All of the shares are being sold by the company, and the underwriters have a 30-day option to buy up …
The operating loss narrowed to $6.8 million from $7.6 million, and the net loss was $6.6 million, or $0.15 per share, versus $7.3 million, or $0.16 per share. An organizational realignment is on track to reach a full run rate of about $1.75 million …
Net income was R$276 million, up 31% from a year ago and 38% from the second quarter. AnnualizedReturn on Equityreached 22.4%, and the efficiency ratio improved 470 basis points to 44.2% as net interest income plus fees grew 9% while operating expenses stayed flat.